Trial Profile
An Open-label Study to Evaluate the Utility of the Apoptosis Imaging Biomarker 18F]ML10 to Assess the Response to Chemotherapy in Patients With Non-Hodgkin's Lymphoma(NHL)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 30 Jun 2023
Price :
$35
*
At a glance
- Drugs Fluorine-18 ML 10 (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Diagnostic use
- Sponsors GlaxoSmithKline; GSK
- 07 Apr 2014 New trial record